Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma.
作者信息
Dhakal Binod, Pagenkopf Adam, Mushtaq Muhammad Umair, Cunningham Ashley M, Flietner Evan, Morrow Zachary, Papadas Athanasios, Hope Chelsea, Leith Catherine, Hematti Peiman, Hari Parameswaran, Callander Natalie S, Asimakopoulos Fotis
机构信息
Department of Medicine, Division of Hematology/Oncology, Medical College of Wisconsin , Milwaukee , WI , USA.
Department of Medicine, Division of Hematology-Oncology, University of Wisconsin-Madison , Madison , WI , USA.
出版信息
Leuk Lymphoma. 2019 Oct;60(10):2558-2562. doi: 10.1080/10428194.2019.1585836. Epub 2019 Mar 8.
Abstract
摘要
相似文献
1
Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma.多功能蛋白聚糖蛋白水解作用可预测骨髓瘤患者的免疫效应细胞浸润及移植后生存率。
Leuk Lymphoma. 2019 Oct;60(10):2558-2562. doi: 10.1080/10428194.2019.1585836. Epub 2019 Mar 8.
2
Immunoregulatory roles of versican proteolysis in the myeloma microenvironment.多功能蛋白聚糖蛋白水解在骨髓瘤微环境中的免疫调节作用。
Blood. 2016 Aug 4;128(5):680-5. doi: 10.1182/blood-2016-03-705780. Epub 2016 Jun 3.
3
Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer.多功能蛋白聚糖衍生的基质因子调节Batf3依赖性树突状细胞分化并促进结直肠癌中的T细胞浸润。
J Immunol. 2017 Sep 1;199(5):1933-1941. doi: 10.4049/jimmunol.1700529. Epub 2017 Jul 28.
4
Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma.多发性骨髓瘤自体移植后，来那度胺维持治疗持续时间延长可带来更长生存期。
Leuk Lymphoma. 2019 Feb;60(2):511-514. doi: 10.1080/10428194.2018.1473577. Epub 2019 Jan 8.
5
Bone marrow microenvironmental CD4 + and CD8 + lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma--an analysis from the Austrian Myeloma Registry.骨髓微环境中CD4⁺和CD8⁺淋巴细胞浸润模式决定标准风险多发性骨髓瘤的总生存期和无进展生存期——来自奥地利骨髓瘤登记处的分析
Leuk Lymphoma. 2016;57(6):1478-81. doi: 10.3109/10428194.2015.1099646. Epub 2015 Nov 16.
6
Autologous stem cell transfusions on multiple days in patients with multiple myeloma-Does it matter?多发性骨髓瘤患者多日进行自体干细胞输注——这重要吗？
Hematol Oncol. 2019 Dec;37(5):649-651. doi: 10.1002/hon.2673. Epub 2019 Sep 13.
7
Versican expression is associated with tumor-infiltrating CD8-positive T cells and infiltration depth in cervical cancer.Versican 表达与宫颈癌浸润的 CD8+T 细胞和浸润深度相关。
Mod Pathol. 2010 Dec;23(12):1605-15. doi: 10.1038/modpathol.2010.154. Epub 2010 Aug 20.
8
Marrow-Infiltrating Lymphocytes Are Effective in Multiple Myeloma.骨髓浸润淋巴细胞对多发性骨髓瘤有效。
Cancer Discov. 2015 Jul;5(7):689. doi: 10.1158/2159-8290.CD-RW2015-100. Epub 2015 May 28.
9
Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect.与自体移植相比，多发性骨髓瘤清髓性异基因移植后的长期结局及移植物抗骨髓瘤效应的影响
Bone Marrow Transplant. 2009 Sep;44(5):325-6. doi: 10.1038/bmt.2009.14. Epub 2009 Feb 9.
10
Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma.活化的骨髓浸润淋巴细胞的过继性转移可在多发性骨髓瘤患者的骨髓中诱导出可测量的抗肿瘤免疫。
Sci Transl Med. 2015 May 20;7(288):288ra78. doi: 10.1126/scitranslmed.aaa7014.
引用本文的文献
1
Versican Proteolysis by ADAMTS: Understanding Versikine Expression in Canine Spontaneous Mammary Carcinomas.ADAMTS 对多功能蛋白聚糖的蛋白水解作用：了解犬自发性乳腺癌中 Versikine 的表达
Cancers (Basel). 2024 Dec 4;16(23):4057. doi: 10.3390/cancers16234057.
2
Targets in the Tumour Matrisome to Promote Cancer Therapy Response.肿瘤基质组中促进癌症治疗反应的靶点。
Cancers (Basel). 2024 May 11;16(10):1847. doi: 10.3390/cancers16101847.
3
Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment.浸润性导管癌和浸润性小叶癌的免疫景观揭示了具有不同特征的巨噬细胞驱动的微环境。
Nat Cancer. 2023 Apr;4(4):516-534. doi: 10.1038/s43018-023-00527-w. Epub 2023 Mar 16.
4
The Study of the Extracellular Matrix in Chronic Inflammation: A Way to Prevent Cancer Initiation?慢性炎症中细胞外基质的研究：预防癌症发生的一种途径？
Cancers (Basel). 2022 Nov 29;14(23):5903. doi: 10.3390/cancers14235903.
5
Matrix proteoglycans in tumor inflammation and immunity.肿瘤炎症与免疫中的基质蛋白聚糖。
Am J Physiol Cell Physiol. 2022 Sep 1;323(3):C678-C693. doi: 10.1152/ajpcell.00023.2022. Epub 2022 Jul 25.
6
Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.来自血液和骨髓移植临床研究网络骨髓瘤协作组关于多发性骨髓瘤免疫和细胞治疗的研讨会会议记录。
Transplant Cell Ther. 2022 Aug;28(8):446-454. doi: 10.1016/j.jtct.2022.05.019. Epub 2022 May 21.
7
The Cancer-Immunity Cycle in Multiple Myeloma.多发性骨髓瘤中的癌症-免疫循环
Immunotargets Ther. 2021 Jul 16;10:247-260. doi: 10.2147/ITT.S305432. eCollection 2021.
8
ADAMTS proteases and the tumor immune microenvironment: Lessons from substrates and pathologies.ADAMTS蛋白酶与肿瘤免疫微环境：来自底物和病理学的启示
Matrix Biol Plus. 2020 Dec 30;9:100054. doi: 10.1016/j.mbplus.2020.100054. eCollection 2021 Feb.
9
Concepts of extracellular matrix remodelling in tumour progression and metastasis.肿瘤进展和转移中外细胞基质重塑的概念。
Nat Commun. 2020 Oct 9;11(1):5120. doi: 10.1038/s41467-020-18794-x.
10
Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity.蛋白聚糖和蛋白聚糖基质小肽在癌症进展、炎症和免疫中的作用。
J Histochem Cytochem. 2020 Dec;68(12):871-885. doi: 10.1369/0022155420937098. Epub 2020 Jul 6.
本文引用的文献
1
Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade.骨髓瘤患者在干细胞移植后发生逃逸是 T 细胞耗竭的结果，而 TIGIT 阻断可预防这种逃逸。
Blood. 2018 Oct 18;132(16):1675-1688. doi: 10.1182/blood-2018-01-825240. Epub 2018 Aug 28.
2
IL-10 inducible CD8 regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells.白细胞介素-10 诱导的 CD8 调节性 T 细胞在多发性骨髓瘤患者中富集，并影响抗原特异性 T 细胞的产生。
Cancer Immunol Immunother. 2018 Nov;67(11):1695-1707. doi: 10.1007/s00262-018-2230-0. Epub 2018 Aug 20.
3
TIGIT immune checkpoint blockade restores CD8 T-cell immunity against multiple myeloma.TIGIT 免疫检查点阻断恢复了针对多发性骨髓瘤的 CD8 T 细胞免疫。
Blood. 2018 Oct 18;132(16):1689-1694. doi: 10.1182/blood-2018-01-825265. Epub 2018 Jul 9.
4
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.自体移植治疗新诊断多发性骨髓瘤在新型诱导药物时代：系统评价和荟萃分析。
JAMA Oncol. 2018 Mar 1;4(3):343-350. doi: 10.1001/jamaoncol.2017.4600.
5
Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer.多功能蛋白聚糖衍生的基质因子调节Batf3依赖性树突状细胞分化并促进结直肠癌中的T细胞浸润。
J Immunol. 2017 Sep 1;199(5):1933-1941. doi: 10.4049/jimmunol.1700529. Epub 2017 Jul 28.
6
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.肿瘤驻留的Batf3树突状细胞是效应T细胞转运和过继性T细胞治疗所必需的。
Cancer Cell. 2017 May 8;31(5):711-723.e4. doi: 10.1016/j.ccell.2017.04.003.
7
Immunoregulatory roles of versican proteolysis in the myeloma microenvironment.多功能蛋白聚糖蛋白水解在骨髓瘤微环境中的免疫调节作用。
Blood. 2016 Aug 4;128(5):680-5. doi: 10.1182/blood-2016-03-705780. Epub 2016 Jun 3.
8
Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.多发性骨髓瘤导致克隆性 T 细胞免疫衰老：识别潜在的促进肿瘤免疫的新靶点及其对检查点阻断的影响。
Leukemia. 2016 Aug;30(8):1716-24. doi: 10.1038/leu.2016.84. Epub 2016 Apr 22.
9
Toll-like Receptor 2 Activation Promotes Tumor Dendritic Cell Dysfunction by Regulating IL-6 and IL-10 Receptor Signaling.Toll 样受体 2 激活通过调节白细胞介素 6 和白细胞介素 10 受体信号转导促进肿瘤树突状细胞功能障碍。
Cell Rep. 2015 Dec 29;13(12):2851-64. doi: 10.1016/j.celrep.2015.11.053. Epub 2015 Dec 17.
10
T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.自体移植后多发性骨髓瘤复发时 T 细胞耗竭：免疫治疗的最佳时机。
Cancer Immunol Res. 2016 Jan;4(1):61-71. doi: 10.1158/2326-6066.CIR-15-0055. Epub 2015 Oct 13.
Zotero 插件